Toggle Side Panel

Alzheimer’s treatment benefits too small to justify cost

max
MariaPCC 19 June 2025

National Institute for Health and Care Excellence (NICE) final draft guidance states the benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) – remain too small to justify the additional cost to the NHS. This means the medicines should not be provided on the NHS as they are not good value for money. Following consultation, a NICE committee’s conclusion in final draft guidance published remains that neither drug can be recommended for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

Categories: News

Report

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.